Exploring a novel crosstalk between hyluronan/CD44 and ErbB-2 pathways in resistance to ErbB-2-targeted therapies in breast cancer

Madera, S; Bulian, VC; Merin, SS; Mercogliano, MF; Schillaci, R; Russo, RIC

CANCER RESEARCH, 2023; 83 (7):